Metraipolis › archive › dc_bbcca591d4bb

Efgartigimod for Guillain-Barré syndrome: rationale, clinical evidence, and future perspectives — Europe PMC PMID:42813052

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42813052
DOI: 10.3389/fimmu.2026.1952646
License (as archived): solo-consultazione
Archived: 2026-10-08T13:10:37.048Z
SHA-256 of the archived text: 6dfb4a4f329406b22c1b6430bfcd48e85311f52fd23a9c79b5d4876c68799fec
Stable URL of this page: https://metraipolis.com/documento/dc_bbcca591d4bb

How to cite

Efgartigimod for Guillain-Barré syndrome: rationale, clinical evidence, and future perspectives — Europe PMC PMID:42813052 — Europe PMC (en), https://europepmc.org/article/MED/42813052 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_bbcca591d4bb (Metraipolis archive dc_bbcca591d4bb, sha256 6dfb4a4f329406b22c1b6430bfcd48e85311f52fd23a9c79b5d4876c68799fec)

BibTeX

@misc{dcbbcca591d4bb,
  title = {Efgartigimod for Guillain-Barré syndrome: rationale, clinical evidence, and future perspectives — Europe PMC PMID:42813052},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42813052},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_bbcca591d4bb; sha256 6dfb4a4f329406b22c1b6430bfcd48e85311f52fd23a9c79b5d4876c68799fec},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42813052. Agents can read the archived copy with the MCP tool read_document.